18 June, 2026
The global landscape of respiratory medicine has reached a new milestone as the European Respiratory Society (ERS) celebrates the latest Journal Citation Reports (JCR) released by Clarivate. The annual release, which serves as the gold standard for measuring the influence and reach of academic journals, has underscored the ERS publishing portfolio’s dominance in the field, with the flagship European Respiratory Journal (ERJ) securing a prestigious second-place ranking within the highly competitive Respiratory System category.
The 2026 report not only reaffirms the ERS’s position as a premier publisher of high-impact scientific content but also highlights a period of robust growth across its entire suite of journals. As global health priorities shift toward managing chronic respiratory diseases and addressing post-pandemic pulmonary recovery, the data reflects an increasing reliance on ERS publications by clinicians, researchers, and policymakers alike.
Main Facts: A Banner Year for ERS Publications
The 2026 Clarivate Journal Citation Reports have brought significant accolades to the European Respiratory Society. The standout performer remains the European Respiratory Journal (ERJ), which has cemented its reputation as a global leader with an impressive Impact Factor of 23.8. This figure places it firmly at the number two spot globally in the Respiratory System category, a testament to the rigorous peer-review standards and the high-caliber clinical and scientific research the journal consistently publishes.
However, the success is not limited to the flagship publication. The ERS publishing program has demonstrated uniform growth, with its supplementary journals—European Respiratory Review, ERJ Open Research, and Breathe—all showing positive trajectories.
- European Respiratory Journal (ERJ): 23.8 Impact Factor (Ranked 2nd globally).
- European Respiratory Review (ERR): 10.8 Impact Factor.
- ERJ Open Research (ERJOR): 4.4 Impact Factor.
- Breathe: 4.5 Impact Factor.
These figures represent more than just numbers; they signify the frequency with which scientific articles from these journals are cited in other peer-reviewed works, serving as a vital metric for the dissemination and utility of medical knowledge.
Chronology: The Road to 2026 Success
The road to these record-breaking metrics has been a deliberate, multi-year strategy focused on open science, digital accessibility, and rigorous quality control.
2023–2024: Strategic Expansion
During this period, the ERS invested heavily in digitizing its submission and peer-review workflows. By streamlining the editorial process, the society ensured that groundbreaking research—ranging from COPD management to novel asthma therapies—could reach the global community with greater speed. This was also the era when ERJ Open Research began to gain significant traction as an alternative to traditional closed-access models.
2025: The Year of Consolidation
In 2025, the editorial boards focused on thematic series, inviting guest editors to curate content around emerging crises, such as climate change impacts on lung health and the rise of antibiotic-resistant respiratory infections. This thematic approach proved highly effective in driving engagement and citations, setting the stage for the strong performance seen in the 2026 Clarivate report.
2026: The Milestone Release
The June 2026 release of the JCR data arrived during a peak period of medical innovation. With the ERS journals having successfully transitioned to more dynamic online delivery platforms, the increased visibility of their research papers contributed directly to the surge in citations observed by Clarivate’s analysts.
Supporting Data: Understanding the Impact Factor
The Impact Factor, as calculated by Clarivate, is derived from the ratio of citations to the number of articles published over a two-year window. While critics often point to the limitations of this metric, it remains the primary currency of academic prestige.
For the ERS, the data indicates a healthy ecosystem of interdisciplinary research. The jump to a 10.8 Impact Factor for European Respiratory Review is particularly notable, as it suggests that researchers are increasingly turning to review articles to synthesize the vast amount of data being generated in respiratory science.
Furthermore, the rise of Breathe to 4.5 reflects a democratization of clinical knowledge. As an educational journal, Breathe bridges the gap between high-level research and bedside practice. The fact that it has achieved such a strong Impact Factor suggests that the journal is not only being read by practitioners but is also being cited in broader clinical guidelines and meta-analyses, which is a significant achievement for a journal centered on continuing medical education.
Official Responses: Gratitude and Future Vision
In the wake of the announcement, the leadership of the European Respiratory Society expressed deep appreciation for the collective effort required to maintain such high standards.
"The achievements reflected in the 2026 Journal Citation Reports are not merely the result of editorial policy; they are a tribute to the global respiratory community," said an ERS spokesperson. "We are immensely grateful to our authors, who entrust us with their most critical work; to our reviewers, who dedicate countless hours to ensuring the integrity of our science; and to our editors, whose vision continues to shape the future of pulmonary medicine."
The ERS leadership emphasized that the focus for the coming year will remain on inclusivity and diversity in research. By encouraging submissions from underrepresented regions and supporting early-career researchers through mentorship programs, the society aims to ensure that its journals remain representative of the global burden of respiratory disease.
Implications: What This Means for the Global Medical Community
The sustained high performance of ERS journals carries several profound implications for the medical and scientific community at large.
1. Influence on Clinical Practice
When a journal like the European Respiratory Journal carries an Impact Factor of 23.8, it becomes a mandatory resource for clinicians drafting new clinical guidelines. The research published within its pages is more likely to influence hospital protocols, drug approval processes, and public health policies. Consequently, the high metrics act as a seal of quality that practitioners rely on to ensure they are using evidence-based medicine.
2. Attracting Top-Tier Talent
For researchers, publishing in high-impact journals is essential for career advancement and securing grant funding. The 2026 JCR update effectively positions the ERS portfolio as the premier destination for the world’s leading respiratory scientists. This creates a "virtuous cycle"—as the best researchers submit their work to ERS, the journals’ impact factors rise further, which in turn attracts even more high-quality research.
3. The Shift toward Open Access
The strong performance of ERJ Open Research (4.4) is a bellwether for the broader publishing industry. As funders increasingly demand that publicly funded research be made available to the public for free, the ERS’s successful implementation of an open-access model suggests a sustainable path forward. It demonstrates that open access does not require a sacrifice in academic rigor or prestige.
4. Global Health Advocacy
The ERS journals are not just repositories for data; they are tools for advocacy. By providing a platform for research into environmental triggers of asthma and the long-term effects of respiratory illness, the society uses its reach to lobby governments and health organizations for better funding and cleaner air initiatives. The 2026 rankings provide the society with increased leverage when advocating for these systemic changes.
Looking Ahead: Sustaining Momentum
As the medical field moves into the second half of the decade, the European Respiratory Society faces the challenge of maintaining its trajectory. The rapid advancement of Artificial Intelligence in medical diagnostics, the aging global population, and the ongoing emergence of respiratory pathogens mean that the demand for reliable, high-impact research will only continue to grow.
The ERS has signaled that its future strategy will involve:
- Enhanced Digital Integration: Utilizing AI to help readers navigate the vast library of ERS content.
- Sustainability Initiatives: Reducing the carbon footprint of its physical and digital operations.
- Broadening Global Reach: Strengthening ties with respiratory societies in Asia, Africa, and Latin America to ensure a truly global perspective in its journals.
For those looking to contribute to this vibrant ecosystem, the call for submissions remains open. As the ERS website notes, the society is always seeking original research, clinical case studies, and systemic reviews that push the boundaries of current knowledge. By contributing to ERS publications, researchers are not just adding to their bibliography—they are participating in a tradition of excellence that, as of 2026, has once again proven to be among the most influential in the world.
Conclusion
The 2026 Clarivate Journal Citation Reports serve as a powerful validation of the European Respiratory Society’s commitment to excellence. With the European Respiratory Journal leading the charge and the entire portfolio demonstrating growth and relevance, the ERS is well-positioned to continue its role as the primary catalyst for progress in respiratory medicine. For the researchers, doctors, and patients who rely on these journals, the future of respiratory health looks not only promising but exceptionally well-documented.
For those interested in contributing to the ongoing success of the ERS publishing program, submissions are currently being accepted. More information on submission guidelines and editorial requirements can be found at the ERS Manuscript Central portal.
